{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:23:45Z","timestamp":1787228625684,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030710","name":"Musculoskeletal Injury Rehabilitation Research for Operational Readiness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tranon.2026.102883","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:31:08Z","timestamp":1782232268000},"page":"102883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical translation of an immunomodulatory cell therapy that is designed to convert \u201ccold\u201d tumors to \u201chot\u201d: A phase 2B trial in 3L MSS\/pMMR metastatic colorectal cancer"],"prefix":"10.1016","volume":"71","author":[{"given":"A.","family":"Hirschfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.N.","family":"Al Hallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-980X","authenticated-orcid":false,"given":"M.","family":"Cusnir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Piyapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Lausoontornsiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Shane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9342-9337","authenticated-orcid":false,"given":"M.","family":"Har-Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.tranon.2026.102883_bib0001","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2174\/18735592MTEx9NTk2y","article-title":"Colorectal cancer epidemiology: recent trends and impact on outcomes","volume":"22","author":"Baidoun","year":"2021","journal-title":"Curr. Drug Targets"},{"issue":"8","key":"10.1016\/j.tranon.2026.102883_bib0002","first-page":"894","article-title":"Application of immune checkpoint inhibitors in colorectal cancer","volume":"46","author":"Wang","year":"2021","journal-title":"Zhong. Nan. Da Xue Xue Bao Yi. Xue Ban."},{"issue":"4\u20135","key":"10.1016\/j.tranon.2026.102883_bib0003","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1159\/000320053","article-title":"Chronic inflammation, colorectal cancer and gene polymorphisms","volume":"28","author":"Boland","year":"2010","journal-title":"Dig. Dis."},{"key":"10.1016\/j.tranon.2026.102883_bib0004","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/OTT.S500281","article-title":"Progress of Immune checkpoint inhibitors therapy for pMMR\/MSS metastatic colorectal cancer","volume":"17","author":"Qu","year":"2024","journal-title":"Onco Targets. Ther."},{"issue":"5","key":"10.1016\/j.tranon.2026.102883_bib0005","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","article-title":"The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: a systematic review","volume":"29","author":"Guven","year":"2024","journal-title":"Oncologist"},{"issue":"2 Suppl","key":"10.1016\/j.tranon.2026.102883_bib0006","first-page":"S31","article-title":"Sequencing considerations in the third-line treatment of metastatic colorectal cancer","volume":"30","author":"Barzi","year":"2024","journal-title":"Am. J. Manage. Care"},{"issue":"3","key":"10.1016\/j.tranon.2026.102883_bib0007","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bbmt.2008.11.036","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience","volume":"15","author":"Aglietta","year":"2009","journal-title":"Biol. Blood Marrow TransPlant."},{"issue":"6","key":"10.1016\/j.tranon.2026.102883_bib0008","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1177\/03008916020016s111","article-title":"Allogeneic non-myeloablative peripheral-blood stem cell transplant in solid tumors","volume":"1","author":"Peccatori","year":"2002","journal-title":"Suppl. Tumori."},{"issue":"6","key":"10.1016\/j.tranon.2026.102883_bib0009","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.mehy.2007.10.008","article-title":"The anti-tumor effect of allogeneic bone marrow\/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?","volume":"70","author":"Har-Noy","year":"2008","journal-title":"Med. Hypotheses"},{"issue":"12","key":"10.1016\/j.tranon.2026.102883_bib0010","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.leukres.2008.05.007","article-title":"Completely mismatched allogeneic CD3\/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity","volume":"32","author":"Har-Noy","year":"2008","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.tranon.2026.102883_bib0011","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2008.08.017","article-title":"Allogeneic CD3\/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia\/lymphoma","volume":"33","author":"Har-Noy","year":"2009","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.102883_bib0012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"issue":"17","key":"10.1016\/j.tranon.2026.102883_bib0013","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.3390\/cancers15174245","article-title":"Immunotherapy for colorectal cancer with high microsatellite instability: the ongoing search for biomarkers","volume":"15","author":"Ros","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.tranon.2026.102883_bib0014","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jamaoncol.2020.1046","article-title":"Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis","volume":"6","author":"Petrelli","year":"2020","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102883_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bulcan.2018.08.007","article-title":"Why is immunotherapy effective (or not) in patients with MSI\/MMRD tumors?","volume":"106","author":"Nebot-Bral","year":"2019","journal-title":"Bull. Cancer"},{"issue":"14","key":"10.1016\/j.tranon.2026.102883_bib0016","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/1078-0432.CCR-23-0824","article-title":"Of context, quality, and complexity: fine-combing tumor mutational burden in immunotherapy-treated cancers","volume":"31","author":"Niknafs","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.tranon.2026.102883_bib0017","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s43018-021-00247-z","article-title":"Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer","volume":"2","author":"Westcott","year":"2021","journal-title":"Nat. Cancer"},{"issue":"9","key":"10.1016\/j.tranon.2026.102883_bib0018","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136368","article-title":"Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer","volume":"5","author":"Kim","year":"2020","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.tranon.2026.102883_bib0019","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-10-2907","article-title":"Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer","volume":"71","author":"Tosolini","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102883_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/4835318","article-title":"Implications for tumor microenvironment and epithelial crosstalk in the management of gastrointestinal cancers","volume":"2019","author":"Ge","year":"2019","journal-title":"J. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102883_bib0021","article-title":"Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: a propensity score-matched analysis","volume":"2","author":"Ye","year":"2019","journal-title":"Cancer Rep. (Hoboken)"},{"issue":"5","key":"10.1016\/j.tranon.2026.102883_bib0022","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102883_bib0023","first-page":"1139","article-title":"Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles","volume":"14","author":"Rodallec","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102883_bib0024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.tranon.2026.102883_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2017.10.002","article-title":"Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms","volume":"322","author":"Davoodzadeh Gholami","year":"2017","journal-title":"Cell Immunol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102883_bib0026","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41587-025-02597-w","article-title":"Turn cold tumors hot by reprogramming the tumor microenvironment","volume":"43","author":"Yuan","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.tranon.2026.102883_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111272","article-title":"Pervasive conditional selection of driver mutations and modular epistasis networks in cancer","volume":"40","author":"Iranzo","year":"2022","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.tranon.2026.102883_bib0028","first-page":"141","article-title":"Predictive biomarkers of response to immune checkpoint inhibitors","volume":"44","author":"Diaz-Carrasco","year":"2020","journal-title":"Farm. Hosp."},{"issue":"4","key":"10.1016\/j.tranon.2026.102883_bib0029","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102883_bib0030","article-title":"Recent advances in the development and efficacy of anti-cancer vaccines-a narrative review","volume":"13","author":"Kielbowski","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.tranon.2026.102883_bib0031","first-page":"607","article-title":"Review. Colon cancer vaccines: an update","volume":"24","author":"Merika","year":"2010","journal-title":"In Vivo"},{"issue":"1","key":"10.1016\/j.tranon.2026.102883_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.1891814","article-title":"Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer","volume":"18","author":"Yu","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.tranon.2026.102883_bib0033","article-title":"Advances and challenges in neoantigen prediction for cancer immunotherapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2026.102883_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1105420","article-title":"Designing neoantigen cancer vaccines, trials, and outcomes","volume":"14","author":"Biswas","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.tranon.2026.102883_bib0035","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.molonc.2015.10.016","article-title":"In situ vaccination: cancer immunotherapy both personalized and off-the-shelf","volume":"9","author":"Hammerich","year":"2015","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102883_bib0036","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.currproblcancer.2015.10.003","article-title":"The immune mechanisms of abscopal effect in radiation therapy","volume":"40","author":"Grass","year":"2016","journal-title":"Curr. Probl. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102883_bib0037","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12967-020-02363-3","article-title":"Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak","volume":"18","author":"Har-Noy","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tranon.2026.102883_bib0038","first-page":"43","article-title":"A phase 2, multicenter, open-label study of AlloStim in-situ cancer vaccine immunotherapy as 3L therapy in MSS\/pMMR metastatic colorectal cancer","author":"Har-Noy","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10395","key":"10.1016\/j.tranon.2026.102883_bib0039","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.102883_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1480704","article-title":"A real-world study: third-line treatment options for metastatic colorectal cancer","volume":"14","author":"Wu","year":"2024","journal-title":"Front. Oncol."},{"issue":"9863","key":"10.1016\/j.tranon.2026.102883_bib0041","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.tranon.2026.102883_bib0042","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.102883_bib0043","article-title":"Racial disparities in metastatic colorectal cancer outcomes revealed by tumor microbiome and transcriptome analysis with bevacizumab treatment","volume":"14","author":"Feng","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"20","key":"10.1016\/j.tranon.2026.102883_bib0044","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.tranon.2026.102883_bib0045","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of Fruquintinib vs Placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA, J. Am. Med. Assoc."},{"issue":"8","key":"10.1016\/j.tranon.2026.102883_bib0046","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/1078-0432.CCR-20-3416","article-title":"Regorafenib-Avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial","volume":"27","author":"Cousin","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102883_bib0047","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.intimp.2018.03.018","article-title":"Pseudoprogression and hyperprogression after checkpoint blockade","volume":"58","author":"Wang","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"31","key":"10.1016\/j.tranon.2026.102883_bib0048","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102883_bib0049","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials","volume":"3","author":"Long","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.tranon.2026.102883_bib0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria","volume":"88","author":"Tazdait","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2026.102883_bib0051","doi-asserted-by":"crossref","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","journal-title":"Cancer Biol. Med."},{"issue":"16","key":"10.1016\/j.tranon.2026.102883_bib0052","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1158\/1078-0432.CCR-17-0114","article-title":"Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions","volume":"23","author":"Nishino","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.tranon.2026.102883_bib0053","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2026.102883_bib0054","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.clon.2024.06.002","article-title":"Pooled rate of pseudoprogression, patterns of response, and tumor burden analysis in patients undergoing immunotherapy oncologic trials for different malignancies","volume":"36","author":"Morrissey","year":"2024","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"10.1016\/j.tranon.2026.102883_bib0055","doi-asserted-by":"crossref","DOI":"10.1186\/s41231-024-00174-y","article-title":"Objective response after immune checkpoint inhibitors in a chemotherapy-refractory pMMR\/MSS metastatic rectal cancer patient primed with experimental AlloStim\u00ae immunotherapy","volume":"9","author":"Hirschfeld","year":"2024","journal-title":"Transl. Med. Commun."},{"issue":"1","key":"10.1016\/j.tranon.2026.102883_bib0056","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/jcrt.jcrt_1898_22","article-title":"Immune checkpoint inhibitors: assessment of the performance and the agreement of iRECIST, irRC, and irRECIST","volume":"20","author":"Yirgin","year":"2024","journal-title":"J. Cancer Res. Ther."},{"issue":"8","key":"10.1016\/j.tranon.2026.102883_bib0057","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jamaoncol.2023.1648","article-title":"Rates of and factors associated with patient withdrawal of consent in cancer clinical trials","volume":"9","author":"Hillman","year":"2023","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102883_bib0058","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.apjon.2021.12.015","article-title":"Participation in and withdrawal from cancer clinical trials: a survey of clinical research coordinators","volume":"9","author":"Kim","year":"2022","journal-title":"Asia Pac. J. Oncol. Nurs."},{"issue":"18","key":"10.1016\/j.tranon.2026.102883_bib0059","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus Nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:25:13Z","timestamp":1787225113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":59,"alternative-id":["S1936523326002202"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102883","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical translation of an immunomodulatory cell therapy that is designed to convert \u201ccold\u201d tumors to \u201chot\u201d: A phase 2B trial in 3L MSS\/pMMR metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102883"}}